Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that spironolactone has shown effectiveness in improving hair density and reducing shedding in female pattern hair loss, particularly for women with hyperandrogenism, though benefits often diminish after stopping treatment.

In this retrospective study, researchers found that while combination therapy of spironolactone and oral minoxidil for female alopecia commonly led to mild outpatient-manageable side effects, starting both medications simultaneously reduced hypertrichosis risk, but taking multiple blood pressure medications increased hypotensive symptoms.

In this study, researchers evaluated the effects of green spinach leaf extract on hair growth in New Zealand rabbits and found that the 15% concentration formula resulted in the highest average hair growth compared to other concentrations and controls.

This study assessed Palestinian women newly diagnosed with breast cancer and found that higher spiritual well-being is associated with improved body image and sexual functioning, and reduced distress from treatment side effects, suggesting spiritual support should be integrated into cancer care.

This analysis reports no significant differences between spironolactone and metformin for managing PCOS, noting spironolactone remains a potential off-label option for patients unable to use hormonal contraceptives, but larger studies are necessary to confirm its efficacy.

This study observed that spiritual well-being significantly correlates with quality of life aspects in newly diagnosed Palestinian women with breast cancer, where factors like inner peace and faith predicted better body image and reduced distress from hair loss.

In a rodent study, researchers found that oral phenytoin and spironolactone significantly mitigated 5-fluorouracil-induced hair loss and oxidative stress, suggesting potential therapeutic benefits for chemotherapy-induced alopecia and enhanced recovery.

This study found that oral spironolactone 100 mg daily for 24 weeks improved terminal hair counts and diameters in premenopausal women with female pattern hair loss when used alongside minoxidil, despite a higher incidence of menstrual irregularities.

Spironolactone is safe for treating hair loss in women without causing low blood pressure.

Spironolactone can safely lower blood pressure in patients on other blood pressure medications, but may slightly increase the risk of low blood pressure.

Spirulina extract may effectively promote hair growth and reduce inflammation, offering a natural alternative for hair loss treatment.

This study protocol aims to explore the prevalence of polycystic ovary syndrome among female pediatric patients with spina bifida, focusing on metabolic and phenotypic differences, but reports no new results yet.

This study evaluated the stability of multiple active ingredients in TrichoSol™ for use in alopecia treatments, finding varying stability durations at room temperature—up to 180 days for some ingredients—supporting its use as a compounding vehicle in personalized therapies.

This study suggests that SACM may enhance hair growth more effectively than non-treated ACM, highlighting the potential of S. maxima as a promising agent for use in pharmaceutical and cosmeceutical industries.

Spironolactone helps prevent swelling caused by minoxidil in women with hair loss.

This study found topical finasteride and minoxidil both improved hair loss clinically and trichoscopically more effectively than spironolactone in women with female pattern hair loss.

This study found both topical spironolactone and topical minoxidil to be effective and safe treatments for female pattern hair loss, with mild to marked improvement observed over six months in both treatment groups, though more side effects were noted with minoxidil.

This research observed that in a prospective case series of 11 women with androgenetic alopecia, oral spironolactone improved hair thinning in most patients over 6 to 36 months, with mild side effects reported. However, effectiveness may be limited in advanced cases.

This study reports a rare case of follicular porokeratosis in a diabetic woman, suggesting a potential association with diabetes mellitus in addition to its known presentation with keratotic papules and scalp alopecia.

This abstract reviews the use of spironolactone as a treatment for hormonal acne, female pattern hair loss, and hirsutism due to its antiandrogenic properties and favorable side effect profile, highlighting its value in dermatological therapies.

This review systematically examined recent advancements in spironolactone-loaded nanocarriers, revealing that lipid and vesicular nanoparticles enhance bioavailability and skin penetration for treating androgen-dependent disorders, but highlighted the need for further clinical studies to optimize their use.

This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.

This review discusses the disparities in approved treatments and evidence-based guidelines for various chronic skin diseases, highlighting greater unmet medical needs in conditions like hidradenitis suppurativa, alopecia areata, and vitiligo compared to psoriasis and atopic dermatitis.

Both treatment combinations improved hair growth similarly and were safe.

In this study, spironolactone was found to be a safe and effective treatment for acne in women over 25 with abnormal hormone levels, while younger women with normal hormone levels showed less response.

This research review found that spironolactone can significantly improve acne severity more effectively than a placebo, with 73.3% of patients reporting satisfaction despite a 26.7% rate of adverse events among the 1,548 participants studied.

In this study, researchers found that bicalutamide was more effective and had a better safety profile than spironolactone for treating female-pattern hair loss in women aged 18 to 50, based on the Sinclair scale and photographic assessments after 24 weeks of treatment.

Low-dose spironolactone can be effective for treating hair loss in women.

This study showed that spironolactone effectively reduces morbidity and mortality in moderate to severe heart failure with reduced ejection fraction, but its benefits in heart failure with preserved ejection fraction are less clear.

In a systematic review and meta-analysis, this study reported that oral spironolactone showed a 56.60% overall improvement in female pattern hair loss, with better results in combination therapy, but emphasized the need for more research due to varied treatment responses and adverse event rates.